Evidence map›Paper›PMID 38358578›Full record

ArticleGeroScience2024

GrimAge is elevated in older adults with mild COVID-19 an exploratory analysis.

Paola García-delaTorre, Nadia Alejandra Rivero-Segura, Sergio Sánchez-García, Kristhian Becerril-Rojas, Francisco Ernesto Sandoval-Rodriguez, Diana Castro-Morales, Miguel Cruz-Lopez, Miguel Vazquez-Moreno, Ruth Rincón-Heredia, Perla Ramirez-Garcia and 1 more

Open access · greenAbstract read
In one paragraph

Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Paola García-delaTorre *Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, México.
Nadia Alejandra Rivero-Segura *Dirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico.
Sergio Sánchez-GarcíaUnidad de Investigación Epidemiológica y en Servicios de Salud, Área de Envejecimiento, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, Mexico.
Kristhian Becerril-RojasDirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico.
Francisco Ernesto Sandoval-RodriguezDirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico.
Diana Castro-MoralesDirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico.
Miguel Cruz-LopezUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, Mexico.
Miguel Vazquez-MorenoUnidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720, Mexico City, Mexico.
Ruth Rincón-HerediaUnidad de Imagenología, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Mexico City, Mexico.
Perla Ramirez-GarciaDirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico.
Juan Carlos Gomez-VerjanDirección de Investigación, Instituto Nacional de Geriatría (INGER), 10200, Mexico City, Mexico. jverjan@inger.gob.mx.ORCID 0000-0001-7186-8067
Instituto Nacional de Pediatria · MXMexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MX

Funding

Alzheimer's Association ALZ-NAN-22-941933Direccion General de Politicas de Investigación en Salud FPIS2023-INGER-7134
6 · The paper itself

Abstract

COVID-19 has been contained; however, the side effects associated with its infection continue to be a challenge for public health, particularly for older adults. On the other hand, epigenetic status contributes to the inter-individual health status and is associated with COVID-19 severity. Nevertheless, current studies focus only on severe COVID-19. Considering that most of the worldwide population developed mild COVID-19 infection. In the present exploratory study, we aim to analyze the association of mild COVID-19 with epigenetic ages (HorvathAge, HannumAge, GrimAge, PhenoAge, SkinAge, and DNAmTL) and clinical variables obtained from a Mexican cohort of older adults. We found that all epigenetic ages significantly differ from the chronological age, but only GrimAge is elevated. Additionally, both the intrinsic epigenetic age acceleration (IEAA) and the extrinsic epigenetic age acceleration (EEAA) are accelerated in all patients. Moreover, we found that immunological estimators and DNA damage were associated with PhenoAge, SkinBloodHorvathAge, and HorvathAge, suggesting that the effects of mild COVID-19 on the epigenetic clocks are mainly associated with inflammation and immunology changes. In conclusion, our results show that the effects of mild COVID-19 on the epigenetic clock are mainly associated with the immune system and an increase in GrimAge, IEAA, and EEAA.

Indexed as

COVID-19AgedAged, 80 and overAgingEpigenesis, GeneticFemaleHumansMaleMexicoMiddle AgedSARS-CoV-2Severity of Illness IndexAgingCOVID-19DNA damageEpigenetic age accelerationEpigenetic clocksImmune system

Identifiers

PMID38358578
PMCPMC11226692
OpenAlexW4391841955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.